OCREVUS (Genentech, Inc.)
Welcome to the PulseAid listing for the OCREVUS drug offered from Genentech, Inc.. This CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC],Antibodies, Monoclonal [Chemical/Ingredient],Antibodies, Monoclonal, Humanized [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Genentech, Inc. |
| NON-PROPRIETARY NAME: | ocrelizumab |
| SUBSTANCE NAME: | OCRELIZUMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC],Antibodies, Monoclonal [Chemical/Ingredient],Antibodies, Monoclonal, Humanized [Chemical/Ingredient] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2017-03-28 |
| END MARKETING DATE: | 0000-00-00 |
OCREVUS HUMAN PRESCRIPTION DRUG Details:
| Item Description | OCREVUS from Genentech, Inc. |
| LABELER NAME: | Genentech, Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 300(mg/10mL) |
| START MARKETING DATE: | 2017-03-28 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 50242-150_ca2fc3be-ce80-45c3-854a-bb19f400d647 |
| PRODUCT NDC: | 50242-150 |
| APPLICATION NUMBER: | BLA761053 |
Other OCRELIZUMAB Pharmaceutical Manufacturers / Labelers:
